A Randomized Phase 2 Pilot Study of Type I-Polarized Autologous Dendritic Cell Vaccines Incorporating Tumor Blood Vessel Antigen (TBVA)-Derived Peptides in Combination With Dasatinib in Patients With Metastatic Melanoma
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2017
At a glance
- Drugs Dasatinib (Primary) ; Dendritic cell vaccines
- Indications Malignant melanoma
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 26 Oct 2017 Planned End Date changed from 1 Jul 2018 to 1 Dec 2018.
- 26 Oct 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Oct 2018.
- 10 Jun 2017 Biomarkers information updated